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Patient and physician preferences for surgical and adjuvant treatment options for
rectal cancer
Abstract
Hypothesis Patients and their clinicians hold varying preferences for surgical and adjuvant treatment
therapies for rectal cancer.
Design Preferences were determined using the Prospective Measure of Preference.
Setting Royal Prince Alfred and St Vincent's hospitals in Sydney, Australia.
Participants Patients with colorectal cancer were interviewed during their postoperative hospital stay, and
physicians were asked to complete a mailed survey.
Main Outcome Measures The Prospective Measure of Preference method produces 2 outcome measures
of preference: willingness to trade and prospective measure of preference time trade-off.
Results Patients' strongest preference was to avoid a stoma: more than 60% would give up a mean of
34% of their life expectancy to avoid this surgical option. This was followed by treatment options
involving chemoradiotherapy, where more than 50% would give up a mean of almost 25% of their life to
avoid treatment. Surgeons held stronger preferences against all adjuvant options compared with
oncologists (P ≤ .01).
Conclusions Patients had strong preferences against all treatment options, and these preferences
frequently differed from those of physicians. These results highlight the importance of determining
patients' own preferences in the clinical encounter. Furthermore, the diversity of preferences of clinical
subspecialists emphasizes the need for multidisciplinary treatment planning to ensure a balanced
approach to treatment decision making for patients with rectal cancer.
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Phyllis Butow, BA(Hons), DipEd, MClinPsych, MPH, PhD; Glenn Salkeld, BBus, GDipHealthEcon, MPH, PhD;
George Hruby, MBBCh, FRANZCR; Stephen Clarke, MBBS, PhD, FRACP, FAChPM

Hypothesis: Patients and their clinicians hold varying
preferences for surgical and adjuvant treatment therapies for rectal cancer.
Design: Preferences were determined using the Pro-

spective Measure of Preference.
Setting: Royal Prince Alfred and St Vincent’s hospitals
in Sydney, Australia.
Participants: Patients with colorectal cancer were interviewed during their postoperative hospital stay, and
physicians were asked to complete a mailed survey.
Main Outcome Measures: The Prospective Measure
of Preference method produces 2 outcome measures of
preference: willingness to trade and prospective measure of preference time trade-off.

Results: Patients’ strongest preference was to avoid a stoma:
more than 60% would give up a mean of 34% of their life
expectancy to avoid this surgical option. This was followed by treatment options involving chemoradiotherapy, where more than 50% would give up a mean of
almost 25% of their life to avoid treatment. Surgeons held
stronger preferences against all adjuvant options compared with oncologists (Pⱕ.01).
Conclusions: Patients had strong preferences against all
treatment options, and these preferences frequently differed
from those of physicians. These results highlight the importance of determining patients’ own preferences in the clinical encounter. Furthermore, the diversity of preferences of
clinical subspecialists emphasizes the need for multidisciplinary treatment planning to ensure a balanced approach
to treatment decision making for patients with rectal cancer.
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OR MORE THAN A DECADE, A
debate has surrounded the
use of adjuvant therapy for
patients with rectal cancer.
This controversy has led to
distinct variations in clinical practice
guidelines and practice patterns across the
world.1-3 European trials and large metaanalyses have demonstrated that preoperative and postoperative radiotherapy improves local recurrence rates,4-8 and in 1
significant Swedish trial,4 preoperative
treatment improved overall long-term and
cancer-specific survival.
Although the results of randomized
trials are encouraging and help guide physicians, contention stems from the fact that
many of the reported data relate to treatments administered up to 15 years ago,
when surgical techniques would be considered suboptimal by today’s standards.
Therefore, it is argued that if surgery were
optimized using current total mesorectal
excision techniques, radiotherapy may not
necessarily be indicated.9-11 This view,
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however, is not supported by evidence
from the Dutch total mesorectal excision
trial,5 where total mesorectal excision was
mandated but the addition of neoadjuvant radiotherapy still resulted in reduced rates of local recurrence, albeit with
no improvement in 5-year survival.
Although the potential benefits of radiotherapy have been disputed, the adverse effects are well recognized and may
outweigh any advantages. Many patients
will develop permanent bowel problems
greater than the normal rate of surgical adverse effects,12 with short-term effects also
increased for patients receiving radiotherapy.13,14 A particular concern associated with postsurgical irradiation to the
bowel is the potential for irreversible damage that patients must live with for the remainder of their lives.
There are, however, strong indications that combining postoperative radiotherapy with concomitant chemotherapy
for stages II and III (T3-4, N0-1, M0) disease improves local recurrence and dis-
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tant metastases.15,16 Currently, efforts are being directed
at investigating the effects of combination therapy in the
preoperative setting, which are not as well defined. One
recent study17 concluded that after 5 years of follow-up,
preoperative compared with postoperative combination
therapy improved local control and was associated with
reduced toxic effects, thus enhancing the therapeutic ratio. Again, any possible benefits must be weighed against
adverse effects. To the adverse effects of radiotherapy are
added further acute complications associated with chemotherapy.
Given the lack of consensus about the role of adjuvant therapy in rectal cancer and the quality-of-life implications, patients’ own preferences or values for each
different treatment combination and outcome should become a key component of clinical decision making and
informed consent. Therefore, this study was undertaken to assess patients’ own preferences for different treatment options for rectal cancer and to compare these preferences with those of colorectal surgeons and medical and
radiation oncologists answering as if they themselves were
patients with rectal cancer (patient surrogates).
METHODS
Verbal scripts were developed to explain 5 treatment scenarios for locally advanced rectal cancer (T3-4, N0-1, M0; stage
II-III) in a standardized manner. These scenarios were chosen
because of difficulties balancing differential benefits and harms
of each treatment. Information was based on the most current
evidence available. For all the scenarios, a low anterior resection (AR) was used as the standard comparator. The 5 treatment choices were (1) low AR compared with low AR plus postoperative radiotherapy, (2) low AR compared with low AR plus
preoperative radiotherapy, (3) low AR compared with low AR
plus chemotherapy, (4) low AR compared with low AR plus
chemoradiotherapy, and (5) low AR compared with abdominoperineal resection (APR). The final scenario was included
to enable patients’ preferences for each adjuvant option to be
compared with what has been documented consistently as a
surgical procedure that patients prefer to avoid.18,19

PROSPECTIVE MEASURE OF PREFERENCE
During a face-to-face interview, each treatment scenario, including the benefits, risks, and likely long-term outcomes, was
described. Once the patient had reached a level of understanding sufficient to make an informed treatment choice, patient
preferences were elicited using the Prospective Measure of Preference method.18,19 Patients were asked how much of their remaining life expectancy they would be willing to trade (give
up) to avoid each adjuvant therapy or an APR. The Prospective Measure of Preference method produces 2 measures of preference. The first measure is a dichotomous variable (yes/no)
of willingness to trade (WTT) any life expectancy to avoid the
nonstandard therapy and is summarized as the proportion of
the group overall that would be willing to trade. The second
measure, a prospective measure of preference time trade-off
(PMPt), is summarized as the mean proportion of remaining
life expectancy traded. Previous studies have demonstrated a
PMPt range of 0 to 0.11.18 A PMPt greater than 0.10 is a measure of a strong preference against treatment. The patient questionnaire also obtained demographic and clinical information
(age, sex, country of birth, language spoken at home, educa-

tional level, marital and employment status, number of dependents, preoperative therapy, site of primary cancer, surgical procedure, and stage of disease).

DEVELOPMENT OF QUESTIONNAIRE
FOR PHYSICIANS
The same questionnaire was adapted to a self-administered format to be mailed to physicians. Physicians were asked to respond as if they themselves were patients with rectal cancer (surrogate patients).

VALIDATION OF QUESTIONNAIRES
The questionnaires were pilot tested to confirm test-retest reliability and the effect of format (face-to-face or written) on responses. Thirty clinical staff and 10 patients each completed
the questionnaire on 2 occasions, 1 week apart, with the format (written or verbal) in random order.

PATIENT RECRUITMENT AND INCLUSION
AND EXCLUSION CRITERIA
Patients with colorectal cancer (Duke stages A-C) admitted to
2 teaching hospitals for curative surgery were eligible to participate. Patients who were cognitively impaired, who were
deemed too unwell by their treating physician, or who were
emergency admissions were considered ineligible. For non–
English-speaking patients, an interpreter was arranged through
the hospital interpreter service. Under ethical guidance, all the
patients were interviewed within a few days of surgery and at
a time before pathology results were available or definitive postoperative treatment plans had been decided. A previous study18
highlighted that patient preferences remained stable from the
preoperative to the postoperative period.

SPECIALIST PHYSICIAN RECRUITMENT
All members of the Colorectal Surgical Society of Australasia
(colorectal surgeons) and the Medical Oncology Group of
Australia (medical oncologists) and radiation oncologists of
the Royal Australian and New Zealand College of Radiologists were surveyed. Physicians were considered ineligible if
they were not practicing medicine, were on extended leave of
more than 6 weeks, or were no longer resident in Australia.
Two reminder letters were sent to nonrespondents. Institutional ethics committee approval was obtained for the study to
proceed.

STATISTICAL ANALYSIS
Statistical analysis was performed blind to participants’ group
status (patient, surgeon, or radiation or medical oncologist).
For each scenario, WTT was compared between groups using
2 tests, whereas the PMPt was compared using Wilcoxon rank
sum tests. Within-group WTT and PMPt were compared between scenarios using McNemar tests or Wilcoxon signed rank
tests as appropriate. Results were compared in patients with
colon vs rectal cancer. Independent predictors of WTT responses were assessed using logistic regression modeling. Potential predictors included in the model were those exhibiting
Pⱕ.25 in univariate analysis,20 and these were then sequentially eliminated using a backward, stepwise approach until all
remaining predictors were significant (P⬍.05). Analysis was
performed using a software program (SPSS; SPSS Inc, Chicago, Illinois).
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SAMPLE SIZE

Table 1. Characteristics of the 103 Study Patients

The WTT ranged from 0.20 to 0.54 across scenarios in a previous colorectal study.18 Assuming a similar distribution, 100
patients would be needed to estimate the PMPt, with 95% confidence intervals of ±9%. To detect at least a 10% difference in
the mean PMPt, at least 36 participants were needed per group
to achieve a power of 80% at a significance level of .05 assuming a 15% standard deviation of preference scores as reported
previously.18

Variable

RESULTS

VALIDATION OF QUESTIONNAIRES
Test-retest comparisons of WTT and PMPt were highly
correlated (R=0.72-0.96) for all but 1 scenario for 1 group.
The impact of format did not affect responses, with strong
correlations (R=0.83-0.97) for all but 1 scenario for 2 pilot groups.
RESPONSE RATE
Of 200 patients with colorectal cancer admitted to Royal
Prince Alfred Hospital, 103 were ineligible to participate (11 had clinical contradictions, 27 had metastatic
disease, 14 did not have an appropriate interpreter available, 9 were too unwell, 3 had died, 1 family refused access, 20 were cognitively impaired, 4 were discharged
early, and 14 were missed/emergency admissions/not seen
by clinical nurse specialist), and 22 patients refused. Of
the 97 eligible patients, 75 consented to be interviewed
(77% consent rate). A further 28 patients were recruited
from St Vincent’s Hospital. Patients were recruited during their postoperative hospital stay. Response rates to
the mailed survey were 79% (87 of 110) for colorectal
surgeons, 47% (97 of 206) for radiation oncologists, and
47% (80 of 169) for medical oncologists. Characteristics of the patients are given in Table 1. The mean age
of the patients was 65 years (range, 26-88 years).
PROSPECTIVE MEASURE
OF PREFERENCE OUTCOMES

Patients, No. (%)

Sex
Male
Female
Cancer site
Colon
Rectum
Stage
A
B
C
Da
Nonmalignant neoplasm a
Country of birth
Australia
Other
Language
English
Other
Type of surgery
Anterior resection
Abdominoperineal resection
Colectomy
Hartmann procedure
Transanal excision
Other
Preoperative treatment
None
Radiotherapy
Chemoradiotherapy
a Pathologic

58 (56)
45 (44)
49 (48)
54 (52)
19 (18)
35 (34)
37 (36)
2 (2)
10 (10)
67 (65)
36 (35)
88 (85)
15 (15)
59 (57)
6 (6)
30 (29)
1 (1)
2 (2)
5 (5)
87 (84)
11 (11)
5 (5)

abnormality determined after interview.

Table 2. Patient Preferences for AR and Alternative
Treatment Options

Treatment Option
AR vs AR ⫹ postoperative radiotherapy
AR vs AR ⫹ preoperative radiotherapy
AR vs AR ⫹ chemotherapy
AR vs AR ⫹ chemoradiotherapy
AR vs abdominoperineal resection

Patients,
No.

WTT

Mean
PMPt

101
99
101
100
99

0.52
0.43
0.60
0.52
0.63

0.20
0.17
0.20
0.24
0.34

Abbreviations: AR, anterior resection; PMPt, prospective measure of
preference time trade-off; WTT, willingness to trade.

Patient Preferences
Patient preferences are given in Table 2. Patients’ strongest preference was to avoid a stoma, with almost 65%
(WTT = 0.63) of the group giving up a mean of 34%
(PMPt=0.34) of their life expectancy to avoid this option.
This was found to be significantly higher than for all other
scenarios (Wilcoxon signed rank tests, Pⱕ.003). The lowest preference scores (WTT = 0.43; PMPt = 0.17) were found
for preoperative radiotherapy. For 2 of the remaining options, postoperative radiotherapy and chemoradiotherapy, patients who indicated a preference against treatment did so to a large degree, as reflected by high PMPt
scores. For chemoradiotherapy, the mean amount of life
traded to avoid this treatment (PMPt=0.24) was significantly higher than that for any other adjuvant treatment
options (all Wilcoxon signed rank tests, Pⱕ.03).

Patients With Rectal vs Colon Cancer
For all the scenarios, the mean PMPt values were significantly lower for patients with rectal cancer vs colon
cancer. Patients with colon cancer, therefore, indicated
a stronger aversion to adjuvant treatment than those with
rectal cancer. Avoidance of a stoma was a stronger preference of both groups.
Predictors of Patient Preferences
Independent predictors of WTT are given in Table 3.
A higher level of education predicted WTT for both radiotherapy options, that is, a stronger preference against
adjuvant radiotherapy. After adjusting for level of edu-
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Table 3. Patient Preferences: Independent Predictors
of Willingness to Trade

Independent Predictor

Table 4. Physician Preferences for AR and Alternative
Treatment Options

Multivariate
Association AOR
(95% CI)

Treatment Option and Group
To avoid AR ⫹ postoperative radiotherapy
Colorectal surgeons
Radiation oncologists
Medical oncologists
To avoid AR ⫹ preoperative radiotherapy
Colorectal surgeons
Radiation oncologists
Medical oncologists
To avoid AR ⫹ chemotherapy
Colorectal surgeons
Radiation oncologists
Medical oncologists
To avoid AR ⫹ chemoradiotherapy
Colorectal surgeons
Radiation oncologists
Medical oncologists
To avoid abdominoperineal resection
Colorectal surgeons
Radiation oncologists
Medical oncologists

Treatment Option: AR ⴙ Postoperative Radiotherapy
Educational level
Primary to year 10
1 [Reference]
High school and tertiary
2.61 (1.14-6.02)
Cancer site
Rectum
1 [Reference]
Colon
2.91 (1.26-6.72)
Treatment Option: AR ⴙ Preoperative Radiotherapy
Educational level
Primary to year 10
1 [Reference]
High school and tertiary
4.70 (1.80-12.27)
Cancer site
Rectum
1 [Reference]
Colon
4.71 (1.67-10.38)
Treatment Option: AR ⴙ Chemotherapy
Postoperative treatment accepted
No
1 [Reference]
Yes
0.27 (0.08-0.90)
Preoperative treatment accepted
No
1 [Reference]
Yes
0.23 (0.07-0.76)
APR
Relative/friend has stoma
No
1 [Reference]
Yes
4.78 (1.68-13.74)
Relative/friend had radiotherapy
No
1 [Reference]
Yes
0.15 (0.05-0.43)

Subspecialty Preferences
Physicians’ preferences are given in Table 4. The statistical significance of differences between groups is given
in Table 5. Patient and physician preferences were consistently different for the scenario involving an APR, with
patients exhibiting significantly stronger preferences to
avoid this surgical option. Colorectal surgeons’ greatest
preference was to avoid postoperative radiotherapy
(WTT = 0.91; PMPt = 0.25), whereas radiation oncologists were less likely to trade, indicating less of an aversion toward this option. High proportions of radiation
and medical oncologists were willing to trade to avoid
each treatment; however, the actual amount of years given
up ranged from 5% to 8% (PMPt=0.05-0.08), which was
much less than for surgeons and patients. Surgeons and

WTT

Mean
PMPt

87
76
96

0.91
0.60
0.74

0.25
0.05
0.08

85
94

0.79
0.53
0.71

0.12
0.05
0.06

85
85
96

0.72
0.70
0.69

0.11
0.08
0.05

85
76
95

0.79
0.64
0.72

0.14
0.08
0.07

86
78
95

0.72
0.79
0.88

0.15
0.14
0.14

Abbreviations: AR, anterior resection; PMPt, prospective measure of
preference time trade-off; WTT, willingness to trade.

radiation oncologists consistently expressed divergent
preferences for options that involved radiotherapy, with
surgeons being more averse.
COMMENT

Abbreviations: AOR, adjusted odds ratio; APR, abdominoperineal
resection; AR, anterior resection; CI, confidence interval.

cation, patients with colon cancer were significantly more
likely than those with rectal cancer to trade, indicating
greater aversion to radiotherapy. For the option involving chemoradiotherapy, patients who had undergone preoperative treatment were less likely to trade life expectancy to avoid this treatment. Furthermore, patients who
knew a relative or friend who had had an APR and lived
with a stoma were more likely to indicate a preference
against this surgical option.

Patients,
No.

This study demonstrates that patients hold varying preferences for surgical and adjuvant therapy options for rectal cancer and that these preferences often do not correspond with the preferences of colorectal surgeons and
oncologists answering as if they were patients themselves.
All clinical subspecialties surveyed indicated strong preferences against all options presented to them. Furthermore, the amount of survival that patients and specialists
were willing to forsake to avoid adjuvant treatment was often greater than or comparable with the survival advantages documented in randomized controlled trials corresponding to the clinical scenarios presented.
As expected, patients were most averse to an APR, with
many willing to trade life expectancy in substantial amounts
to avoid this surgical option. The extent to which patients
were averse to this surgery was much greater than anticipated compared with previous studies in colorectal cancer and Crohn disease.18,19 Patients were significantly more
likely to be averse to an APR if they had known or knew a
patient with a stoma. This particular association, to our
knowledge, has not been previously reported and may be
a result of the negative experiences encountered by people
living with a stoma in the community.21,22
For all the adjuvant scenarios, patients who indicated a
preference against treatment did so with a strong degree
of certainty, as shown by the large proportions of life they
would give up (PMPt=0.17-0.24). Previous studies of colorectal conditions18,19 have indicated that a PMPt greater
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than 0.10 is a measure of a strong preference; therefore,
for these adjuvant options, patients expressed particularly
strong views. The large amount of life patients were willing to give up to avoid treatment is also significant considering the elderly demographic of this patient group. Patients would more likely trade to avoid options involving
chemotherapy. This finding is consistent with a previous
study18 exploring patient views of treatment for colon cancer and most probably reflects concerns for the effects of
treatment on quality of life.
The results of this study suggest that if patients are
offered adjuvant therapy they would most likely opt for
preoperative radiotherapy. From a patient’s perspective
it is plausible that preoperative treatment may be viewed
as a more favorable option because of its relatively short
duration compared with other regimens and the fact that
treatment may be complete once surgery has been performed. Furthermore, any potential damage to the bowel
due to presurgical irradiation is likely to be removed during surgery, which is appealing from a quality-of-life perspective. The preference for preoperative treatment may
also be a reflection of coping style among patients whereby
those who have a problem-focused coping style may prefer to “get all the treatment over with” as quickly as
possible.23,24
In this study, patients with rectal cancer were more
willing to accept all adjuvant treatment options, as indicated by lower WTT and PMPt values, compared with
patients with colon cancer. Furthermore, the site of cancer was found to be an independent predictor of preference for both radiotherapy options. This finding highlights that the choices and values of patients who are
actually facing the treatment decisions differ from those
who are not. Although some of this variation can be explained by cognitive dissonance reduction25 in the group
of patients with rectal cancer who had preoperative treatment (n=11), this cannot explain all the difference. These
findings have important methodological implications for
future studies and emphasize the importance of recruiting actual patients to quantify preferences.
Specialists’ preferences were generally significantly
higher than those of patients, particularly among surgeons. Differences in preferences between patients and
physicians are not uncommon, and this finding is consistent with other studies in colorectal,18 breast,26 and prostate cancer27 and end-of-life decisions.28 Concordance of
50% to 80% has been reported,27 and it has been shown
that predictions of treatment preferences more closely resemble the views of the surrogate than the actual preferences of the individual facing treatment. Although it
is acknowledged that physicians have to make decisions
for their patients on an individual basis, such discordance may have implications for clinical decision making and patient referral pathways. Specialist treatment recommendations remain an important predictor of treatment
choice, with patients likely to ask their physicians for the
treatment they would prefer.29,30 The present study suggests that surgeons acting as patient surrogates would be
less likely to recommend adjuvant therapy. It is also plausible that such strongly held preferences may affect the
likelihood that surgeons refer their patients to oncology
consultations. These attitudes may partially explain why

Table 5. Statistical Significance of Differences Between
Patients, Surgeons, and Radiation and Medical Oncologists
for Alternative Treatment Options a
Comparison Group
To avoid AR ⫹ postoperative radiotherapy
Patients vs colorectal surgeons
Patients vs radiation oncologists
Patients vs medical oncologists
Colorectal surgeons vs radiation oncologists
Colorectal surgeons vs medical oncologists
Radiation vs medical oncologists
To avoid AR ⫹ preoperative radiotherapy
Patients vs colorectal surgeons
Patients vs radiation oncologists
Patients vs medical oncologists
Colorectal surgeons vs radiation oncologists
Colorectal surgeons vs medical oncologists
Radiation vs medical oncologists
To avoid AR ⫹ chemotherapy
Patients vs colorectal surgeons
Patients vs radiation oncologists
Patients vs medical oncologists
Colorectal surgeons vs radiation oncologists
Colorectal surgeons vs medical oncologists
Radiation vs medical oncologists
To avoid AR ⫹ chemoradiotherapy
Patients vs colorectal surgeons
Patients vs radiation oncologists
Patients vs medical oncologists
Colorectal surgeons vs radiation oncologists
Colorectal surgeons vs medical oncologists
Radiation vs medical oncologists
To avoid abdominoperineal resection
Patients vs colorectal surgeons
Patients vs radiation oncologists
Patients vs medical oncologists
Colorectal surgeons vs radiation oncologists
Colorectal surgeons vs medical oncologists
Radiation vs medical oncologists

WTT b

PMPt c

⬍.001
.16
⬍.001
⬍.001
.01
.09

.01
.03
.26
⬍.001
⬍.001
.16

⬍.001
.18
⬍.001
⬍.001
.14
.02

.07
.30
.74
⬍.001
⬍.001
.02

⬍.001
⬍.001
.001
.84
.52
.67

.62
.99
.54
.51
.001
.01

⬍.001
.08
⬍.01
.04
.23
.35

.94
.11
.17
⬍.01
.001
.87

.26
.03
⬍.001
.26
⬍.01
.11

⬍.01
.01
.01
.40
.11
.46

Abbreviations: AR, anterior resection; PMPt, prospective measure of
preference time trade-off; WTT, willingness to trade.
a Test statistics are available from the authors on request.
b P value for 2 test.
c P value for Wilcoxon rank sum test.

currently in Australia there is less than 40% concordance with 2 national clinical guidelines that recommend the use of adjuvant treatment for some patients with
rectal cancer.31
A limitation of this study is the low response rates from
oncologists. Each of the societies surveyed has a broad
membership base, so the survey was likely mailed to physicians with little interest in or experience with rectal cancer. However, previous studies18 involving these groups
have reported similar response rates, with respondents
most likely interested in gastrointestinal tract disorders.
This study also was performed before the Swedish Rectal Cancer Trial4 reported long-term survival benefits, so
these data could not be included in the treatment scenarios. However, the issues of optimal surgical techniques and the impact of treatment on quality of life remain unresolved.
In conclusion, patients and physicians were able to
trade life expectancy to indicate a preference for various
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adjuvant and surgical options for rectal cancer. Patients
had strong preferences against all treatment options, and
they frequently differed from those of physicians. These
results highlight the importance of determining patients’ own preferences in the clinical encounter. Furthermore, the diversity of preferences of clinical subspecialists emphasizes the need for multidisciplinary
treatment planning to ensure a balanced approach to treatment decision making for patients with rectal cancer.
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